Post-Paclitaxel: Will Boston Scientific Cut Guidant Royalty Deal?
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific's reluctance to grant Medtronic a license in 2001 in its dispute over rapid-exchange delivery technology may set a precedent for the next stage of the Boston Scientific/Guidant fight over drug-eluting stents